Molecular Partners AG (NASDAQ:MOLN – Get Free Report) shares dropped 0.6% during trading on Tuesday . The stock traded as low as $5.36 and last traded at $5.36. Approximately 6,640 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 7,505 shares. The stock had previously closed at $5.39.
Analyst Upgrades and Downgrades
Separately, Leerink Partnrs raised shares of Molecular Partners to a “strong-buy” rating in a research report on Monday, October 7th.
View Our Latest Research Report on MOLN
Molecular Partners Price Performance
Molecular Partners Company Profile
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is a Low P/E Ratio and What Does it Tell Investors?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What Are Dividend Achievers? An Introduction
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
